Background: Oral propranolol accelerates the involution of infantile haemangiomas (IHs). However, it is not clear whether IHs treated with oral propranolol are associated with fewer sequelae than when left untreated.
Objectives: To quantify and describe sequelae associated with IHs treated with oral propranolol, and to explore whether treated IHs are associated with fewer sequelae than untreated IHs.
Materials & Methods: This multicentre, retrospective, cohort study included patients with IH treated with oral propranolol ≥2 mg/kg for at least six months, with photographic images available at baseline and at age 4-5 years. A historical comparison cohort comprised 185 patients with untreated IHs. Main outcomes/measures were: IH features, treatment characteristics and type/degree of sequelae.
Results: Oral propranolol, most commonly at 2 mg/kg/day (mean duration: nine months), was initiated in 171 patients (mean age: 6.02 months). After treatment, 125 of 171 (73.1%) IHs were associated with no/minimal sequelae. The most common sequelae were telangiectasia (78%), fibrofatty tissue (37%) and anetodermic skin (28%). Deep IHs were associated with significantly fewer sequelae than other subtypes. Ulceration appeared to increase the likelihood of severe sequelae. IHs with a stepped border was associated with more severe sequelae than those with a progressive border (44% versus 27%, p < 0.05). Treated IHs resolved without sequelae or were associated with a sequela that did not need correction in 27.7% more cases than untreated IHs (RR: 1.61; p < 0.001).
Conclusion: Among IHs treated with oral propranolol, 73% resolved without, or were associated with minimal sequelae. Deep IHs were associated fewer sequelae than other subtypes. Oral propranolol decreased the likelihood of IH sequelae requiring correction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1684/ejd.2021.4172 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of Orofacial Infantile Haemangioma: A Case Report.
Case Rep Dent
December 2024
Department of Paediatric Dentistry, Selayang Hospital (Ministry of Health), Batu Caves, Selangor, Malaysia.
Infantile haemangioma (IH) is the most common childhood tumour, often developing in the head and neck region. It may cause disfigurement, functional impairment, or tooth developmental issues when it is present in the oral cavity. We report a case of a 2-month-old boy referred to the paediatric dentistry team with a segmental IH involving the left periorbital, cheek, and hard palate.
View Article and Find Full Text PDFEfficacy and safety of oral propranolol and topical timolol in the treatment of infantile hemangioma: a meta-analysis and systematic review.
Front Pharmacol
December 2024
Department of Pediatric Surgery, Guangzhou Women and Children's Medical Center, National Children's Medical Center for South Central Region, Guangzhou Medical University, Guangzhou, China.
Background: Propranolol, a nonselective β-blocker, is the first-line treatment for infantile hemangioma (IH). Topical timolol has recently been proposed as a novel IH treatment with fewer adverse effects. This study was conducted to compare the efficacy and safety of oral propranolol and topical timolol for treating IH.
View Article and Find Full Text PDFCombining treatments for migraine prophylaxis: the state-of-the-art.
J Headache Pain
December 2024
Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
Combination treatments for migraine prophylaxis present a promising approach to addressing the diverse and complex mechanisms underlying migraine. This review explores the potential of combining oral conventional prophylactics, onabotulinumtoxin A, monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway, and small molecule CGRP receptor antagonists (gepants). Among the most promising strategies, dual CGRP inhibition through mAbs and gepants may enhance efficacy by targeting both the CGRP peptide and its receptor, while the combination of onabotulinumtoxin A with CGRP treatments offers synergistic pain relief.
View Article and Find Full Text PDFEfficacy of Propranolol and Pingyangmycin combination therapy in infantile hemangiomas: Correlation with VEGF levels.
J Stomatol Oral Maxillofac Surg
November 2024
Oral and Maxillofacial Surgery Department, Wuxi Stomatological Hospital 214000, Wuxi, PR China. Electronic address:
Article Synopsis
- The study focuses on evaluating the effectiveness of a treatment combining propranolol and pingyangmycin for infantile hemangiomas (IH), which are common vascular tumors in infants that can grow rapidly.
- Over 12 months, 120 children participated, with results showing significant reductions in both the Hemangioma Activity Score and serum levels of vascular endothelial growth factor (VEGF), indicating improved condition with treatment.
- The treatment was mostly well-tolerated, with mild and temporary side effects reported in 15% of patients, and there was a strong negative correlation between VEGF levels and hemangioma activity, suggesting the therapy's effectiveness relates to lowering VEGF.
Diagnosis and Treatment of Infantile Hemangioma from the Primary Care Paediatricians to the Specialist: A Narrative Review.
Children (Basel)
November 2024
Pediatric Unit, Department of Surgical Sciences, Destiny, Gynecology and Pediatrics, University of Verona, 37126 Verona, Italy.
Infantile haemangiomas (IHs) affect 3-10% of infants, 10% of whom need topical or systemic beta-blocker therapy. Propranolol is the first choice for IHs with a high risk of complications. Since more than half of IHs leave a permanent mark, to reduce outcomes, it is essential to start oral propranolol (2-3 mg/kg/day in 2 doses/day) within the 5th month of life (i.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!